Nerispirdine

Drug Profile

Nerispirdine

Alternative Names: HP-184

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis
  • Class Indoles; Neuroprotectants; Nootropics; Pyridines; Small molecules
  • Mechanism of Action Acetylcholine stimulants; Cholinergic receptor agonists; Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cognition disorders; Multiple sclerosis; Spinal cord injuries

Most Recent Events

  • 01 Mar 2010 sanofi-aventis completes a phase IIb trial in Multiple sclerosis in USA, EU and Canada
  • 01 Dec 2008 Phase-II clinical trials in Multiple sclerosis in Canada (PO)
  • 01 Dec 2008 Phase-II clinical trials in Multiple sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top